Ertumaxomab - CISMeF

Preferred Label : Ertumaxomab;

NCIt synonyms : Anti-CD3 x anti-HER-2-neu Bispecific Monoclonal Antibody;

NCIt definition : A murine monoclonal antibody with two antigen-recognition sites: one for CD3, an antigen expressed on mature T cells, and one for HER-2-neu, a tumor-associated antigen that promotes tumor growth. Ertumaxomab attaches to CD3-expressing T cells and HER-2-neu-expressing tumor cells, selectively cross-linking tumor and immunologic cells which results in the recruitment of cytotoxic T cells to the T cell/tumor cell aggregate.;

UNII : L5L45YGP1O;

CAS number : 509077-99-0;

Details

Origin ID

C2658;

UMLS CUI

C1723386;

Currated CISMeF NLP mapping
- ertumaxomab [MeSH concept]
- ertumaxomab [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- ertumaxomab [MeSH concept]
- ertumaxomab [MeSH Supplementary Concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Receptor Tyrosine-Protein Kinase erbB-2 [NCIt concept]
is_component_of_chemotherapy_regimen
- Anti-CD3 x Anti-HER-2-Neu Bispecific Monoclonal Antibody/Autologous Lymphocytes/Interleukin-2/Sargramostim [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients